PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.38%
Revenue growth of 3.38% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
44.31%
Gross profit growth of 44.31% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
143.07%
EBIT growth of 143.07% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
143.07%
Positive operating income growth while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch would spot a big relative advantage here.
-154.14%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-148.34%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-145.86%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
23.88%
Share change of 23.88% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
23.19%
Diluted share change of 23.19% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-100.98%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-48.44%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.29%
OCF/share CAGR of 82.29% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
82.29%
OCF/share CAGR of 82.29% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
87.74%
3Y OCF/share growth of 87.74% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-240.94%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-240.94%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.02%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
6.64%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 0.02%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
1674.77%
Equity/share CAGR of 1674.77% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
1674.77%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 39.17%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
3789.23%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 21.34%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
57.85%
AR growth of 57.85% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
43.35%
Inventory growth of 43.35% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
52.48%
Asset growth of 52.48% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
14.24%
BV/share growth of 14.24% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
272.38%
Debt growth of 272.38% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
-50.01%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-24.57%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.